biohacking$bioLLM CA: TBA

database / hormone

Gonadorelin

also known as GnRH, LHRH

approved hormone reproductiveendocrine sequence not characterised
OOOOOOOOOOOOONNNNNNNNNNNNNNNNNHHHHHHHHHHHHHHHHHHH
85 heavy atoms · 165 bonds · drag to pan, scroll to zoom C55N17O13

Skeletal structure drawn from the computed atomic coordinates in PubChem CID 638793. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.

Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.

Sequence

Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.

pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 — begins with pyroglutamate, which has no one-letter code.

Molecular data

Chemical fields come from the PubChem compound record; computed values are derived from the sequence shown above.
molecular formulaC55H75N17O13
molecular weight1182.3 Da (PubChem)
computed backbone massnot characterised
lengthnot characterised
net charge (pH 7.4)not characterised
mean hydropathynot characterised
half-lifenot characterised
delivery routesubcutaneous, intravenous
PubChem CID638793
PDBnot characterised
UniProt parentP01148

Mechanism

GnRH receptor agonist driving LH and FSH release.

Reported targets: GnRHR

Experimental structure

No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.

Parent protein

Cleaved from the GnRH precursor. UniProt P01148 · 92 aa

Reported effects

Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.

Reported observations and the corpus they are drawn from.
reported outcomewhere it appears
LH and FSH releaseEstradiol treatment and double dose of GnRH for resynchronization protocols … Theriogenology 2026

Registered trials

Records from ClinicalTrials.gov. Listed for reference — this project sponsors no trial and is not involved in any of them.
NCTtitlestatusphase
NCT03660813Follicle Size and Oocyte DevelopmentCOMPLETEDNA
NCT06379217NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted RadiACTIVE_NOT_RECRUITINGPHASE1
NCT04500743Role of Suppression of Endometriosis With Progestins Before IVF-ETCOMPLETEDNA
NCT02678520Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer PatientsWITHDRAWNPHASE2
NCT01395940A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)COMPLETEDPHASE2

Literature (8)

Estradiol treatment and double dose of GnRH for resynchronization protocols and timed artificial insemination in lactating dairy cows — Theriogenology 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 41101065 · DOI 10.1016/j.theriogenology.2025.117707

Diagnostic accuracy of the triptorelin stimulation test for central precocious puberty in girls — Endocrine connections 2025

Graphical abstractAbstractCentral precocious puberty (CPP) results from premature activation of the hypothalamic-pituitary-gonadal axis. The GnRH stimulation test remains the diagnostic gold standard, especially in girls with undetectable basal LH levels. However, native GnRH is expensive and often unavailable. Rapid-acting subcutaneous triptorelin has been proposed as a reliable alternative. This retrospective study evaluated the diagnostic accuracy of subcutaneous triptorelin compared with intravenous gonadorelin and investigated the optimal timing for LH peak assessment. A total of 341 girls referred for suspected precocious puberty were evaluated: 102 underwent the triptorelin test and 239 the gonadorelin test, with gonadotropins measured by electrochemiluminescence assay at baseline and after stimulation. Based on clinical, radiological, and laboratory criteria, 143 girls were diagn…

open access ↗ · PMID 41384863 · DOI 10.1530/ec-25-0642

Diagnostic performance of a simplified GnRH stimulation test in central precocious puberty: a multicentre study — Research Square 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · DOI 10.21203/rs.3.rs-9526415/v1

Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone release, ovulatory response, and pregnancy in first-service lactating dairy cows — Journal of dairy science 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 41698585 · DOI 10.3168/jds.2025-27334

Diagnostic Usefulness of Subcutaneous Triptorelin Stimulation Testing in the Evaluation of Central Precocious Puberty in Girls — Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 41956123 · DOI 10.1055/a-2844-9524

Reproductive efficiency of Bos indicus cows under different estradiol-free ovulation synchronization protocols — Theriogenology 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 41538921 · DOI 10.1016/j.theriogenology.2026.117830

Effects of Kisspeptin on rabbit ovulation: a comprehensive study of ovulatory, endocrine and histological response — Theriogenology 2025

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 40505597 · DOI 10.1016/j.theriogenology.2025.117524

Luteinizing Hormone-Releasing Hormone (LHRH)-Targeted Treatment in Ovarian Cancer — International journal of molecular sciences 2025

Ovarian cancer remains one of the most lethal gynecologic malignancies and requires more effective and targeted treatment strategies. Luteinizing hormone-releasing hormone (LHRH), or gonadotropin-releasing hormone (GnRH), receptors are expressed in approximately 80% of ovarian tumors, representing a promising target for targeted drug delivery. This narrative review aimed to explore the development and advancements of LHRH-receptor targeted therapies in ovarian cancer. A bibliographic search was performed using PubMed, Scopus, Google Scholar, and Web of Science. The search strategy included studies on LHRH-peptide drug delivery systems and LHRH-conjugate nanosystems. Literature search covered in vitro studies, preclinical models, and ongoing clinical trials from 2000 to 2025. A total of 19 studies were included for peptide-drug delivery, and 30 studies were included for LHRH-conjugated na…

open access ↗ · PMID 41465311 · DOI 10.3390/ijms262411884

Related

Glucagon

hormone · 8 citations

Ghrelin

hormone · 8 citations

Oxytocin

hormone · 8 citations

Vasopressin

hormone · 8 citations

Kisspeptin-10

hormone · 8 citations

Insulin

hormone · 8 citations